JuSun
Concept of the company Pharvaris NVNASDAQ: PHVS) up ~58% On Thursday after the Dutch biopharma reported that a Phase 2 trial of the candidate angioedema (HAE) PHVS416 met the main goals as an oral treatment needed for HAE attacks.
RAPIDe-1 trials was designed to demonstrate PHVS416, an investigational soft gel capsule, as a treatment for angioedema in 74 patients with Type I or II HAE.
Test subjects received one-third of a single dose of PHVS416 and placebo in two doses.
Part I covers the administration of a single dose of PHVS416 at the study site during a non-scheduling period. In Phase II, patients self-administered blinded study medication at home in response to HAE attacks.
According to the above, RAPIDe-1 met the primary endpoint, significantly reducing the symptoms of HAE, according to the change in visual analog scale (VAS-3), which considers skin pain, skin inflammation, abdominal pain, from hospital to hospital. four hours after treatment.
RAPIDe-1 also met all the important secondary endpoints, including reducing the time to onset of symptoms, which showed a ≥30% reduction in the VAS-3 score from the initial presentation.
PHVS416 caused treatment-related adverse events, and no patient discontinued treatment due to complications.
Pharvaris ( PHVS ) continues to enroll patients outside the US in the PHVS416 study in HAE after the FDA suspended the PHA121 trial, including RAPIDe-1.
In line with the benchmark data, the company announced Q3 2022 financial results, which show revenues of €198M and the same as Sep. 30.
